狄诺塞麦怎么注射？

(Denosumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth. Denosumab inhibits tumor growth and reduces bone destruction by binding to RANKL and preventing it from activating RANK on the surface of osteoclasts, osteoclast precursors and osteoclast-like giant cells.

The FDA approved this product for use in postmenopausal women with osteoporosis who are at high risk for fractures. It can help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. This product is also used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures.

The FDA approved denosumab for the treatment of bone metastases from solid tumors based on the results of three published pivotal clinical trials. A comprehensive analysis of these three studies showed that compared with zoledronic acid, denosumab prolonged the time to first adverse bone event (ARE) in patients by 17%, or significantly delayed the median time to first SRE by 8.2 months (27.6 months vs. 19.4 months). months), denosumab also prolonged the time from first onset to recurrence of SRE by 18% in the study; in addition, for patients with mild or no pain at study enrollment, denosumab also significantly prolonged the time to worsening pain compared with zoledronic acid.

So how should denosumab be injected? The specific methods are: (1) It can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.